The car t-cell therapy condition center is a comprehensive resource for clinical news and expert insights on car t-cell therapy. Read more at OncLive.
December 20th 2024
Andrew Ip, MD, discusses comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma.
December 11th 2024
Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.
December 10th 2024
Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.
Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.
December 9th 2024
Tisagenlecleucel maintained long-term efficacy and safety in relapsed/refractory follicular lymphoma.
December 8th 2024
Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia
December 7th 2024
Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.
December 3rd 2024
Jennifer Amengual, MD, discusses real-world outcomes with CAR T-cell therapy and bispecific antibodies in patients with DLBCL.
Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.
December 2nd 2024
In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.
November 29th 2024
Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.
November 26th 2024
Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.
November 22nd 2024
Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.
November 20th 2024
David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.
November 19th 2024
Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.
November 11th 2024
Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.
November 9th 2024
Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.
November 8th 2024
The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.
November 1st 2024
Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.